Are we able to Manage Effectively Opioid-Induced Bowel Dysfunction?

Wojciech Leppert*
Department of Palliative Medicine, Poznan University of Medical Sciences, Poznan, Poland

Opioid-Induced Bowel Dysfunction

Opioid-Induced Bowel Dysfunction (OIBD) is commonly associated with the chronic use of opioid analgesics and affects 80-90% of treated patients [1]. OIBD comprises constipation, anorexia, nausea and vomiting, gastro-esophageal reflux, delayed digestion, abdominal pain, flatulence, bloating, hard stool, straining during bowel movement and incomplete evacuation. In some cases, it may lead to more serious complications such as bowel faecal impaction with overflow diarrhoea and faecal incontinence, pseudo-obstruction (that may cause anorexia, nausea and vomiting), disturbance of drug absorption, urine retention and urine incontinence. OIBD may decrease patients’ compliance and in consequence inappropriate opioid dosing and insufficient analgesia. OIBD also significantly deteriorates patients’ quality of life. One third of patients treated with opioid analgesics does not adhere to the prescribed opioid regimen or simply quit the treatment due to OIBD symptoms [2].

Outline of Patomechanism of Opioid-Induced Bowel Dysfunction

The patomechanism of OIBD comprises both peripheral and central mechanisms. The peripheral opioid effect on \( \mu \)-opioid receptors in the gut wall plays the main role here [3]. High density of \( \mu \)-opioid receptors was found in neurons of myenteric and submucosal plexus and immune cells in the lamina propria [4]. opioid receptors (predominantly \( \mu \), also \( \kappa \) and \( \delta \)) are located in the gut wall in the myenteric plexus and in the submucosal plexus. The former are responsible for GI motility and the latter for secretion. The \( \mu \)-opioid receptors are activated in the wall of the stomach, small and large intestine by endogenous (enkephalins, endorphins and dynorphins) and exogenous (codeine, dihydrocodeine, hydrocodone, tramadol, morphine, oxycodone, hydromorphone, fentanyl, buprenorphine, methadone) opioids and modify GI function. Activation of \( \mu \)-opioid receptors inhibits excitatory and inhibitory neural pathways within the enteric nervous system that coordinates motility. Inhibition of excitatory neural pathways depresses peristaltic contractions. The blockade of inhibitory neural pathways increases GI muscle activity, elevates resting muscle tone, spasms and non-propulsive motility patterns. These mechanisms are responsible for delayed gastric emptying and slowing the intestinal transit [5]. The central mechanism of opioid effects on GI tract was demonstrated as intracerebroventricular administration of morphine in rats inhibited gastrointestinal propulsion. This effect was reversed by intracerebroventricular administration of naloxone and vagotomy. Intrathecal administration of morphine reduced gastroduodenal motility and intramuscular morphine gave additional effects. Thus both central and peripheral opioid effects play a role in opioid GI effects [6].

Treatment of Opioid-Induced Bowel Dysfunction

General measures comprise the meticulous assessment and applying prophylactic measures matched to patients' general condition. Change of diet (increased food and fluid intake), more physical activity, sitting position during bowel movement and privacy during defeation process are recommended. Patients treated with opioids should be considered for prokinetic administration (metoclopramide, domperidone, itopyrid) [7]. Reversible causes such as hypercalcaemia should also be treated. Discontinuing or decreasing doses of drugs that may contribute to constipation development (such as tricyclics, neuroleptics, anticholinergics) should also be considered. Patients and families should be educated about the ways of prevention and treatment of OIBD. In majority of patients with OIBD laxatives need to be administered. The general recommendation is to combine oral administration of osmotic agents (usually lactulose or macrogol) which have an osmotic effect in the colon with stimulants activating neurons in the myenteric and submucosal plexus in colon and reducing absorption of water and electrolytes from the intraluminal contents: anthracenes (senna), polyphenolics (bisacodyl) or sodium picosulphate [8].

However, these drugs display limited efficacy in patients suffering from OIBD; moreover, they may cause several adverse effects and must be administered on a regular basis. Other groups of laxatives are faecal lubricants (liquid paraffin), stool softeners (surfactants: sodium docusate); however they are usually ineffective when administered alone. The use of bulk-forming agents such as fibre, bran, methylcellulose and psyllium seeds has limited role in patients with OIBD and advanced disease as enough fluids (at least 2 l per day) should be co-administered and may lead to viscous mass formation and pseudo obstruction development [9]. Castor oil is not recommended due to its sudden stimulating effect on bowel motility and the risk of developing strong abdominal cramps. If the oral laxatives are found to be ineffective, rectal treatment is considered. The possibility of opioid switch in the treatment of OIBD should be considered usually rotating codeine to tramadol and morphine to transdermal fentanyl. However, in contrast to clinical studies [10,11], observational surveys do not provide evidence for advantages of transdermal fentanyl over other opioid analgesics with respect to bowel function [12,13].

New approach comprises opioid antagonists with peripherally restricted mode of action as is the case with methylnaltrexone [14] or both central and peripheral effects such as naloxone. However, naloxone is nearly completely inactivated in the liver and has negligible systemic bioavailability when administered orally in controlled-release tablets with oxycodone in a dose ratio 1:2. Oxycodone provides analgesia and naloxone acts only in gastrointestinal tract blocking \( \mu \)-opioid receptors and preventing constipating effect of oxycodone [15]. Both methylnaltrexone and naloxone do not evoke opioid withdrawal symptoms and may be used in OIBD, especially when oral laxatives are ineffective [16]. Such an approach allows avoiding rectal measures that may affect patients' quality of life [17]. However, long-term safety

*Corresponding author: Wojciech Leppert, Chair and Department of Palliative Medicine, Poznan University of Medical Sciences, Osiedle Rusa 25 A, 61 – 245 Poznan, Poland, Tel: +48 61 8738 303; E-mail: wojciech.leppert@wp.pl

Received May 11, 2012; Accepted May 14, 2012; Published May 16, 2012

Citation: Leppert W (2012) Are we able to Manage Effectively Opioid-Induced Bowel Dysfunction?. J Autacoids 1:e113. doi:10.4172/2161-0479.1000e113

Copyright: © 2012 Leppert W. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
of opioid receptor antagonists are not well established [18,19] and high costs of such therapies may be an important issue, although recent pharmacoeconomic analyses of oxycodone/naloxone provided encouraging results [20].

Summary

Returning to the question in the title are we really effective in the treatment of OIBD? It seems that we have made a huge progress introducing recently opioid receptor antagonists to clinical practice either acting as peripheral only antagonist effects (methylaltrexone) that is effective in 50-60% of treated patients or a central and peripherally acting antagonists (naloxone) in combination with an opioid analgesic oxycodone which significantly reduces the constipating effect of oxycodone. However, we have limited data on efficacy and safety of both approaches. Traditional treatment remains symptomatic and not targeted on a real cause of the symptoms. So we are on the beginning of the road that should give a positive answer to the question. But we have also the privilege to be part of development in this fascinating area that not only opens up a new chapter in the science but above all has a clear positive impact on patients’ quality of life.

References